Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101
- 22 July 2019
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 37 (7) , 311-324
Abstract
Enthusiasms into the application of PI3K-δ inhibitor CAL-101 has been muted due to the over-activation of compensatory molecules. Our results delineated that c-Myc suppression using 10058-F4 enhanced CAL-101 cytotoxicity in less sensitive cells through different mechanisms based on p53 status; while CAL-101-plus-10058-F4 induced G1 arrest in wild-type p53-expressing leukemic cells, no conspicuous increase in G1 was noted in U937 cells harboring mutant p53. Conclusively, this study shed lights on the role of c-Myc oncoprotein in acute leukemia cells sensitivity to PI3K inhibitor and outlined that the combination of c-Myc inhibitor and CAL-101 may be a promising therapeutic approach in leukemia.Keywords
This publication has 43 references indexed in Scilit:
- Myc inhibition impairs autophagosome formationHuman Molecular Genetics, 2013
- An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor ResistanceClinical Cancer Research, 2013
- MYC on the Path to CancerCell, 2012
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancerNature Chemical Biology, 2011
- Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood, 2010
- Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in miceCancer Chemotherapy and Pharmacology, 2008
- Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesisCancer Cell, 2006
- Role of Tyrosine Kinase Inhibitors in Cancer TherapyThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Targeted cancer therapyNature, 2004
- PI3K/Akt signalling pathway and cancerCancer Treatment Reviews, 2004